RBC Cuts Insys Therapeutics (INSY) PT By 27%

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. TSLA
4. NVDA
5. GNK
6. USO
7. AWK
8. ARGX
9. AZN
10. SPCX

Go back to RBC Cuts Insys Therapeutics (INSY) PT By 27%

Jefferies Cuts Price Target on Insys Therapeutics (INSY) Following Preliminary 1Q Subsys Revenues

April 12, 2016 7:57 AM EDT

Jefferies maintained a Buy rating on Insys Therapeutics (NASDAQ: INSY), and cut the price target to $17.00 (from $23.00), following the release of the company's preliminary estimated revenues from Subsys. INSY reported that Subsys Q1 revenues should be $61-62M vs consensus ($86M) forecasts. Many... More

INSYS Therapeutics' (INSY) Price Target Reduced to $28 at Piper Jaffray

April 11, 2016 1:36 PM EDT

Piper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY) and reduced its price target to $28.00 (from $46.00).

For an analyst ratings summary and ratings history on INSYS Therapeutics click here. For more ratings news on INSYS Therapeutics click here.

Shares of INSYS Therapeutics closed at $17.66 yesterday.

... More

Insys Therapeutics (INSY) Offers Prelim. Q1 Subsys Revenue; Notes Drop in Volumes

April 11, 2016 6:51 AM EDT

Insys Therapeutics, Inc. (Nasdaq: INSY) announced that its preliminary estimated revenues from Subsys® (fentanyl sublingual spray) for the first quarter of 2016 will be in the range of $61 million to $62 million. Estimated revenues for the quarter reflect a decline in demand, as Subsys... More